Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | FAAH | O00519 | 9/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19067107 | 0.84 | DGKA (0.47) | FAAHKMT2A | |
| SCHEMBL2223792 | 0.84 | DGKA (0.47) | FAAHKMT2A | |
| SCHEMBL18960980 | 0.84 | DGKA (0.47) | FAAHKMT2A | |
| SCHEMBL4812972 | 0.84 | DGKA (0.47) | FAAHKMT2A | |
| SCHEMBL26031851 | 0.83 | GAA (0.49) | GAAFAAHRECQLMEN1KMT2A | |
| SCHEMBL1000814 | 0.83 | GAA (0.49) | GAAFAAHRECQLMEN1KMT2A | |
| SCHEMBL10060985 | 0.83 | GAA (0.49) | GAAFAAHRECQLMEN1KMT2A | |
| SCHEMBL209163 | 0.82 | DGKA (0.44) | FAAHKMT2AALDH1A1HPGD | |
| SCHEMBL28168374 | 0.77 | ALDH1A1 (0.42) | FAAHRECQLMEN1KMT2AALDH1A1 | |
| SCHEMBL18796560 | 0.75 | RECQL (0.81) | GAAFAAHRECQLMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265430-A1 | RNAi Agents for Inhibiting Expression of DUX4, Compositions Thereof, And Methods of Use | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2023-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265430-A1 | RNAi Agents for Inhibiting Expression of DUX4, Compositions Thereof, And Methods of Use | ZFX, DDX39B, DDX21 | GAA 927/4885FAAH 3378/4885RECQL 819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.